171 related articles for article (PubMed ID: 20654019)
21. Measures of 6-mercaptopurine and methotrexate maintenance therapy intensity in childhood acute lymphoblastic leukemia.
Nielsen SN; Grell K; Nersting J; Frandsen TL; Hjalgrim LL; Schmiegelow K
Cancer Chemother Pharmacol; 2016 Nov; 78(5):983-994. PubMed ID: 27600880
[TBL] [Abstract][Full Text] [Related]
22. Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia.
Dervieux T; Hancock ML; Pui CH; Rivera GK; Sandlund JT; Ribeiro RC; Boyett J; Evans WE; Relling MV
Clin Pharmacol Ther; 2003 Jun; 73(6):506-16. PubMed ID: 12811360
[TBL] [Abstract][Full Text] [Related]
23. The association between fasting hypoglycemia and methylated mercaptopurine metabolites in children with acute lymphoblastic leukemia.
Melachuri S; Gandrud L; Bostrom B
Pediatr Blood Cancer; 2014 Jun; 61(6):1003-6. PubMed ID: 24415675
[TBL] [Abstract][Full Text] [Related]
24. Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood.
Toyoda Y; Manabe A; Tsuchida M; Hanada R; Ikuta K; Okimoto Y; Ohara A; Ohkawa Y; Mori T; Ishimoto K; Sato T; Kaneko T; Maeda M; Koike Ki; Shitara T; Hoshi Y; Hosoya R; Tsunematsu Y; Bessho F; Nakazawa S; Saito T
J Clin Oncol; 2000 Apr; 18(7):1508-16. PubMed ID: 10735899
[TBL] [Abstract][Full Text] [Related]
25. A comparison of red blood cell thiopurine metabolites in children with acute lymphoblastic leukemia who received oral mercaptopurine twice daily or once daily: a Pediatric Oncology Group study (now The Children's Oncology Group).
Bell BA; Brockway GN; Shuster JJ; Erdmann G; Sterikoff S; Bostrom B; Camitta BM;
Pediatr Blood Cancer; 2004 Aug; 43(2):105-9. PubMed ID: 15236274
[TBL] [Abstract][Full Text] [Related]
26. Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of childhood: a Pediatric Oncology Group study.
Camitta B; Leventhal B; Lauer S; Shuster JJ; Adair S; Casper J; Civin C; Graham M; Mahoney D; Munoz L
J Clin Oncol; 1989 Oct; 7(10):1539-44. PubMed ID: 2778483
[TBL] [Abstract][Full Text] [Related]
27. De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo.
Dervieux T; Brenner TL; Hon YY; Zhou Y; Hancock ML; Sandlund JT; Rivera GK; Ribeiro RC; Boyett JM; Pui CH; Relling MV; Evans WE
Blood; 2002 Aug; 100(4):1240-7. PubMed ID: 12149204
[TBL] [Abstract][Full Text] [Related]
28. Population pharmacokinetic and pharmacogenetic analysis of 6-mercaptopurine in paediatric patients with acute lymphoblastic leukaemia.
Hawwa AF; Collier PS; Millership JS; McCarthy A; Dempsey S; Cairns C; McElnay JC
Br J Clin Pharmacol; 2008 Dec; 66(6):826-37. PubMed ID: 18823306
[TBL] [Abstract][Full Text] [Related]
29. Use of allopurinol in children with acute lymphoblastic leukemia to reduce skewed thiopurine metabolism.
Brackett J; Schafer ES; Leung DH; Bernhardt MB
Pediatr Blood Cancer; 2014 Jun; 61(6):1114-7. PubMed ID: 24376133
[TBL] [Abstract][Full Text] [Related]
30. Systemic exposure to mercaptopurine as a prognostic factor in acute lymphocytic leukemia in children.
Koren G; Ferrazini G; Sulh H; Langevin AM; Kapelushnik J; Klein J; Giesbrecht E; Soldin S; Greenberg M
N Engl J Med; 1990 Jul; 323(1):17-21. PubMed ID: 2355954
[TBL] [Abstract][Full Text] [Related]
31. Mercaptopurine-induced fever: hypersensitivity reaction in a patient with acute lymphoblastic leukemia.
Chen LJ; Nightingale G; Baer MR
Pharmacotherapy; 2010 Jan; 30(1):113. PubMed ID: 20030482
[TBL] [Abstract][Full Text] [Related]
32. Dose reduction of coadministered 6-mercaptopurine decreases myelotoxicity following high-dose methotrexate in childhood leukemia.
Nygaard U; Schmiegelow K
Leukemia; 2003 Jul; 17(7):1344-8. PubMed ID: 12835723
[TBL] [Abstract][Full Text] [Related]
33. Polymorphism of ITPA 94C>A and risk of adverse effects among patients with acute lymphoblastic leukaemia treated with 6-mercaptopurine.
Wan Rosalina WR; Teh LK; Mohamad N; Nasir A; Yusoff R; Baba AA; Salleh MZ
J Clin Pharm Ther; 2012 Apr; 37(2):237-41. PubMed ID: 21545474
[TBL] [Abstract][Full Text] [Related]
34. Multidrug resistance protein 4 (MRP4) polymorphisms impact the 6-mercaptopurine dose tolerance during maintenance therapy in Japanese childhood acute lymphoblastic leukemia.
Tanaka Y; Manabe A; Fukushima H; Suzuki R; Nakadate H; Kondoh K; Nakamura K; Koh K; Fukushima T; Tsuchida M; Koike K; Kiyokawa N; Noguchi E; Sumazaki R; Komiyama T
Pharmacogenomics J; 2015 Aug; 15(4):380-4. PubMed ID: 25403995
[TBL] [Abstract][Full Text] [Related]
35. Isolated decrease in factor V in children treated by 6-Mercaptopurine for acute lymphoblastic Leukemia.
Filhon B; Dumesnil C; Van Dreden P; Schneider P; Vasse M; Vannier JP
Thromb Res; 2014 Nov; 134(5):1164-6. PubMed ID: 25204998
[No Abstract] [Full Text] [Related]
36. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
[TBL] [Abstract][Full Text] [Related]
37. [6-mercaptopurine-related hand-foot syndrome in a four-year-old child].
Giacchero D; Monpoux F; Chiavérini C; Lacour JP
Ann Dermatol Venereol; 2008; 135(8-9):580-3. PubMed ID: 18789293
[TBL] [Abstract][Full Text] [Related]
38. Maintenance Treatment With Low-Dose Mercaptopurine in Combination With Allopurinol in Children With Acute Lymphoblastic Leukemia and Mercaptopurine-Induced Pancreatitis.
Zerra P; Bergsagel J; Keller FG; Lew G; Pauly M
Pediatr Blood Cancer; 2016 Apr; 63(4):712-5. PubMed ID: 26878433
[TBL] [Abstract][Full Text] [Related]
39. Mercaptopurine in childhood leukaemia: the effects of dose escalation on thioguanine nucleotide metabolites.
Lennard L; Welch J; Lilleyman JS
Br J Clin Pharmacol; 1996 Oct; 42(4):525-7. PubMed ID: 8904630
[TBL] [Abstract][Full Text] [Related]
40. High-dose mercaptopurine followed by intermediate-dose cytarabine in relapsed acute leukemia.
Lockhart S; Plunkett W; Jeha S; Ramirez I; Zipf T; Cork A; Pinkel D
J Clin Oncol; 1994 Mar; 12(3):587-95. PubMed ID: 8120558
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]